No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Bioneer Corporation, established in 1992 and headquartered in Daejeon, South Korea, is a biotechnology company involved in diverse fields such as research products, molecular diagnostics, pharmaceuticals, and probiotics. For the biotechnology research market, Bioneer offers a wide array of consumables and reagents, including PCR and RT-PCR kits, real-time PCR solutions, RNA interference products, various chemicals, plastic laboratory essentials, and buffer solutions. The company also provides an extensive range of services like sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher services, electrophoresis, genome-wide functional analysis, and magnetic separation techniques. Additionally, Bioneer manufactures sophisticated instruments for conventional and real-time PCR, sample preparation, protein synthesis, centrifugation, vortex mixing, electrophoresis, spectrophotometry, and microbial culture. In molecular diagnostics, it supplies MDx technologies, human diagnostic kits, MDx extraction kits, and the necessary instrumentation. Furthermore, Bioneer develops specialized products for animal health and cutting-edge nano-biotechnology applications.
www.bioneer.co.krNo one on the platform currently holds 064550.KQ.
No tracked institution reports a position in 064550.KQ as of their last filing.
No one on the platform has traded 064550.KQ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | -1.5% | — | — | — | ||
| Rev. Growth % | 12.3% | 9.8% | ||||
| Profit Margin % | -0.9% | 1.2% | -13.4% | |||
| Free Cash Flow Margin % | 1.1% | -1.7% | -14.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $516.2B | +16.5% | $2687.00 | $2687.00–$2687.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 064550.KQBioneer Corporation | $9860.00 | +3.79% | $254.5B | — |
| 065660.KQAnterogen.Co.,Ltd. | $15230.00 | +1.94% | $152.4B | — |
| 078160.KQMEDIPOST Co., Ltd. | $8700.00 | +0.00% | $340.0B | — |
| 084990.KQHelixmith Co., Ltd | $2935.00 | +0.51% | $135.1B | — |
| 092040.KQAmicogen, Inc. | $833.00 | +1.34% | $47.4B | — |
| 095700.KQGenexine, Inc. | $2805.00 | +0.54% | $127.6B | — |
| 115450.KQHLB Therapeutics Co.,Ltd. | $1996.00 | +2.41% | $176.0B | — |
Source: Financial Modeling Prep · peers by sector/industry